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Finding Cures for Tropical Diseases: Is Open 
Source An Answer? * 
Stephen M. Maurer, Arti Rai & Andrej Sali** 
I. INTRODUCTION 
Tropical diseases affect more than 500 million people, one 
tenth of the world’s population.1  Malaria, for example, kills 
more than one million people each year.2  And yet, only about 
one percent of new drugs treat tropical diseases.3  For diseases 
prevalent in rich countries, patent incentives and commercial 
pharmaceutical houses have created health innovation systems 
that are the envy of the world.  However, the patent system 
does not work for diseases in developing countries, where 
companies cannot sell enough patented products to cover their 
research and development (R&D) costs.  Proposed solutions to 
address this problem fall into two categories: charitable 
adjustments to the patent system and non-profit venture 
capital firms. 
Proposals for charitable adjustments to the patent system 
generally involve using subsidies to prop up drug prices and 
                                                          
 * This article is based on S.M. Maurer, et al., Finding Cures for Tropical 
Diseases: Is Open Source an Answer?, 1 PLOS MED. 3 (2004). 
 ** Stephen M. Maurer is a Visiting Lecturer, Goldman School of Public 
Policy, University of California, Berkeley.  Arti Rai is a Professor of Law at 
Duke University School of Law.  Andrej Sali is a Professor at the Departments 
of Biopharmaceutical Sciences and Pharmaceutical Chemistry and The 
California Institute for Quantitative Biomedical Research, University of 
California, San Francisco. 
 1. See Richard E. Davis, Parasitology and Tropical Diseases, at 
http://www.library.csi.cuny.edu/~davis/faculty_page/Parasit_links/parasitology
_links.html (last visited Sept. 23, 2004). 
 2. WORLD HEALTH ORGANIZATION, INHERITING THE WORLD: THE ATLAS 
OF CHILDREN’S HEATH AND THE ENVIRONMENT 20 (2004), available at 
http://www.who.int/ ceh/publications/en/07malaria.pdf. 
 3. See O. Trouiller & P.L. Olliaro, Drug Development Output from 1975-
1996:  What Proportion for Tropical Diseases, 3 INT’L J. OF INFECTIOUS 
DISEASE 61, 61-63 (1998-1999). 
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restore incentives.4  The problem with this approach, however, 
is determining how large the subsidy should be.  In principle, 
the most cost-effective solution is to set a subsidy that barely 
covers expected R&D costs.  However, determining drug R&D 
costs is difficult.  Published estimates of such costs vary 
widely.5  Set the subsidy too low and nothing will happen.  Set 
the subsidy too high and costs skyrocket.  Cost containment is 
an important issue, and to the best of our knowledge, no 
sponsor has used subsidies to prop up drug prices and restore 
incentives. 
The second approach involving non-profit venture capital 
firms has started to bear fruit.  Today, more than half a dozen 
“Virtual Pharmas” exist.  Unlike conventional pharmaceutical 
houses, “Virtual Pharmaceutical Companies” or “Virtual 
Pharmas” do little or no development in-house.  Instead, they 
develop a portfolio of promising drug candidates through a web 
of agreements with commercial and academic partners.  Like 
their corporate cousins, Virtual Pharmas look for promising 
drug candidates and push development through clever 
contracts with corporate partners.  Today, Virtual Pharma 
manages most of the world’s R&D effort for tropical diseases.6  
They are responsible for most drug candidates currently under 
development.  The challenge is to make them stronger.  Virtual 
Pharmas need more upstream research, particularly in linking 
genomics and chemistry.7  They suffer from constricted 
budgets,8 making cost containment essential.  “Open source 
drug discovery” could alleviate these problems. 
                                                          
 4. See Michael Kremer, Creating Markets for New Vaccines - Part II: 
Design Issues, in INNOVATION POLICY AND THE ECONOMY 73, 73-76 (Adam B. 
Jaffe, Josh Lerner Lerner, & Scott Stern, eds., 2001); Mattias Ganslandt, et 
al., Developing and Distributing Essential Medicines to Poor Countries:  The 
DEFEND Proposal, 24 WORLD ECONOMY 779, 792 (2001); Helping the Poorest, 
THE ECONOMIST, Aug. 14, 1999, at 11. 
 5. See Arnold S. Relman & Marcia Angell, America’s Other Drug 
Problem, THE NEW REPUBLIC, Dec. 16, 2002, at 27, 29-30. 
 6. Personal Communication with Solomon Nwaka, Scientific Officer, 
Medicines for Malaria Venture; Personal Communication with V. Holt, CEO, 
OneWorld Health. 
 7. See Solomon Nwaka & Robert G. Ridley, Virtual Drug Discovery and 
Development for Neglected Diseases Through Public-Private Partnerships, 2 
NATURE REVIEWS: DRUG DISCOVERY 919, 924-25 (2003). 
 8. See generally e.g., MEDICINES FOR MALARIA VENTURE, ANNUAL 
REPORT 2002, 31-38 (2003), available at http://www.mmv.org/filesupld/53.pdf; 
Declan Butler, Gates Steps Up War On Malaria with Donation of $168 Million, 
425 NATURE 331 (2003). 
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A. OPEN SOURCE DRUG DISCOVERY 
To date, open source methods have made little headway 
beyond software.9  However, computing and computational 
biology are converging.  In the same way that programmers 
find bugs and write patches, biologists look for proteins 
(“targets”) and select chemicals (“drug candidates”) that bind to 
them and affect their behavior in desirable ways.  In both 
cases, research consists of finding and fixing tiny problems 
hidden in an ocean of code. 
What would open source drug discovery look like?  In 
analogy with current software collaborations, we propose a Web 
site where volunteers could search and annotate shared 
databases.  Individual pages would host tasks like searching for 
new targets, finding chemicals to attack known targets, and 
posting data from related chemistry and biology experiments.  
There would also be chat rooms and bulletin boards where 
volunteers could announce discoveries and debate future 
research directions.  Over time, the most dedicated and 
proficient volunteers would become leaders.  Just as it does 
today, Virtual Pharma would choose the best candidates and 
develop promising discoveries.10  Most importantly, all 
discoveries would be made available without patents, in a 
manner that maximizes access in the developing world.11 
B. INCENTIVES WITHOUT PATENTS 
Patents are not the only way to elicit innovation.  
Economists have shown that software collaborations appeal to 
a variety of motives including ideology, learning new skills, 
                                                          
 9. See generally Dan L. Burk, Open Source Genomics, 8 B.U. J. SCI. & 
TECH. L. 254, 255 (2002); Kenneth Neil Cukier, Community Property: Open-
source Proponents Plant the Seeds of a New Patent Landscape, 1 ACUMEN 54, 
57-58 (2003) (noting the first seeds of an open source biology movement are 
emerging in bioinformatics), available at http://www.cukier.com/writings/ 
acumen-cukier-oct03.pdf; Janet Hope, Open Source Biotechnology? (2003) 
(describing limitations to open source biology), available at 
http://rsss.anu.edu.au/~janeth/OSBiotech.html. 
 10. Personal Communication with Solomon Nwaka, Scientific Officer, 
Medicines for Malaria Venture; Personal Communication with V. Holt, CEO, 
OneWorld Health. 
 11. For a discussion of the different licenses under which discoveries 
might be available, see S.M. Maurer, et al., Finding Cures for Tropical 
Diseases: Is Open Source an Answer?, 1 PLOS MED. 3 (2004). 
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gaining reputation, and impressing potential employers.12  
These incentives may sound limited, but open source software 
would not exist without them.  Similar incentives should 
motivate biologists.  In fact, gaining reputation through 
publication is a particularly strong motive for academic 
biologists. 
Now consider the universities and corporations who will be 
asked to supply people and resources.  In sharing data, 
research tools, and other inputs, one might expect that 
intellectual property rights would be an issue.  However, a 
sensible manager does not assert rights unless she expects to 
earn a profit.  Since the commercial value of their inputs 
depends almost entirely on U.S. and European markets, 
universities and companies have little to lose by sharing their 
intellectual property with groups that fight tropical diseases.  
In fact, some private firms already do this.13  Additionally, 
sophisticated university licensing offices tolerate open source 
software projects that do not have significant commercial value.  
We think that they will be similarly understanding of open 
source biology with low commercial value.  Life sciences 
companies will probably be equally tolerant.14  The main 
challenge will be to show donors that an open source project 
can keep members from diverting donated information into 
unauthorized commercial research. 
Finally, consider the private companies whose facilities 
will be needed to turn open source discoveries into actual 
drugs.  During the 1950s, the March of Dimes developed polio 
vaccines without any patents at all.15  Instead, corporate 
partners received contract payments to help with development.  
                                                          
 12. See Josh Lerner & Jean Tirole, Some Simple Economics of Open 
Source, 50 J. INDUS. ECON. 197, 212-217 (2002) (discussing programmers’ 
motivations). 
 13. See Dennis Normile, Monsanto Donates Its Share of Golden Rice, 289 
SCIENCE 843, 845 (2000) (describing Monsanto providing “royalty-free licenses 
to speed up work on a genetically modified rice that could alleviate vitamin A 
deficiency around the world); Dennis Normile, Syngenta Agrees to Wider 
Release, 296 SCIENCE 1785, 1785, 1787 (2002) (stating that the Syngenta 
group releasing it’s rice genome sequence on its web site and on CD-ROM); 
Personal Communication with V. Holt, CEO of One World Health. 
 14. Arti Rai, Open and Collaborative Research: A New Model for 
Biomedicine, in INTELLECTUAL PROPERTY RIGHTS IN FRONTIER INDUSTRIES: 
BIOTECHNOLOGY AND SOFTWARE (Robert Hahn, ed., forthcoming 2005).  
 15. See JANE S. SMITH, PATENTING THE SUN 220-23, 338 (William Morrow 
and Co., Inc. 1990) (chronicling the development of the polio vaccine). 
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The arrangement was good business.  While contract profits 
may have been small compared to patents, the risk was also 
small.  Fifty years later, contract research still makes sense.  
Generic drug companies, developing world drug manufacturers, 
contract research organizations, and biotechnology firms have 
all said that they would consider contracts to develop open 
source drug candidates.16 
C. COST CONTAINMENT 
Since the operation would exist mainly on the Web, 
budgets would be more or less the same as existing software 
collaborations.  The exception to this rule, computing time, 
would be expensive but manageable.  Furthermore, today’s 
biologists routinely scrounge resources from university 
machines or borrow time on home computers.17  Open source’s 
most obvious cost saving is that sponsors do not have to pay for 
labor.  But open source’s cost advantage does not end when the 
volunteers go home.  Traditional subsidies create cost 
containment problems.18  Open source would escape this trap 
by making discoveries freely available.  This would allow 
governments and charities to invite companies to bid against 
each other for the right to perform further development under 
contract.  Competitive bidding is a powerful mechanism for 
containing costs.  It is also a good way to develop drugs.  
Virtual Pharma has extensive experience supervising contract 
research.19  Finally, the absence of patents would keep prices 
low once drugs reached the market.  Patents, after all, are 
designed to keep prices high.  U.S. drugs frequently fall to 
about one-fourth of the original price once patents expire. 
                                                          
 16. Personal Communication with Michael Spino, Vice President for 
Scientific Affairs, Apotex Inc.; Personal Communication with S. Sharma, Chief 
Scientific Officer, Nicolas Piramel India Ltd.; Personal Communication with 
Frank Hijek, Director, Therapeutic Development, Duke Clinical Research 
Institute; Personal Communication with Donald P. Francis, Genentech, Inc. 
 17. See, e.g., Stanford University, GENOME@HOME, at 
http://www.stanford.edu/group/pandegroup/genome (last visited Sept. 17, 
2004); University of Oxford, SCREENSAVER LIFESAVER, at 
http://www.chem.ox.ac.uk/curecancer.html (last visited Sept. 17, 2004). 
 18. See Ganslandt, supra note 4, at 792. 
 19. Personal Communication with Solomon Nwaka, Scientific Officer, 
Medicines for Malaria Venture; Personal Communication with V. Holt, CEO, 
OneWorld Health. 
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D. GETTING PHYSICAL 
This Web-centric, low-budget computational approach is 
probably enough to generate new science and ideas for follow-
up experiments.  Although this is a good start, it is not a 
complete solution.  Computational biology works best when it 
can interact with wet chemistry and biology experiments.  
Thus, in practice, an open source drug discovery effort is likely 
to include modest physical experiments. 
To support physical experiments, academic scientists could 
use discretionary resources and, in some cases, tropical disease 
grants.  Furthermore, good science generates its own funding.  
We expect experimentalists to turn the collaboration’s web 
pages into grant proposals.  A truly balanced research program 
would also require sponsors.  Charities could support open 
source drug discovery by making wet chemistry and biology 
experiments a top priority.  Corporations could also help by 
donating funds, laboratory time, or previously unpublished 
results.  One low cost/high value option would be to reveal pre-
existing data whenever the collaboration was about to explore a 
“dry hole.”20 
III. CONCLUSIONS 
So far, we have argued that open source is feasible, but 
what are the risks?  Experience with software collaborations 
highlights the main social and economic challenges.  First, the 
project will have to find and motivate volunteers.  Based on 
existing software collaborations, we estimate a required 
minimum “critical mass” of a few dozen active members.  
Second, modest chemistry and biology experiments can 
increase the chances for success.  Resources of several hundred 
thousand dollars per year – most in the form of in-kind 
donations such as databases, laboratory access, and computing 
time – would make open source drug discovery much more 
powerful.  By most standards, such risks are real but 
acceptable. 
The largest uncertainties are scientific. Can a volunteer 
effort based on computational biology and modest experiments 
produce leads that are promising enough to catch Virtual 
Pharma’s attention?  We have argued that a successful 
                                                          
 20. Personal Communication with Russ Altman, Stanford University. 
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program must (a) make a significant contribution toward 
supplying the genomic insights that Virtual Pharma needs, and 
(b) make useful drug candidates freely available.  Ten years 
ago, these goals would have been unrealistic.  Today, however, 
researchers frequently use computation to find promising 
protein targets and lead compounds.21  Open source drug 
discovery looks feasible.  The only way to be sure is to perform 
the experiment. 
 
                                                          
 21. See Marcin von Grotthus, Lucjan S. Wyrwicz, & Leszek Rychlewski, 
MRNA Cap-1 Methyltransferase in the SARS Genome, 113 CELL 701, 701-02 
(2003) (using computing to identify a protein of the SARS virus); Brian K. 
Shoichet et al., Lead Discovery Using Molecular Docking, 6 CURRENT OPINION 
IN CHEM. BIOLOGY 439 (2002).  See generally Christine S. Ring et al., 
Structure-Based Inhibitor Design by Using Protein Models for the Development 
of Antiparasitic Agents, 90 PNAS. 3583 (1993). 
